Hua Medicine

HKSE:02552 (China)  
HK$ 1.59 (0%) Apr 23
At Loss
P/B:
14.45
Market Cap:
HK$ 1.56B ($ 198.60M)
Enterprise V:
HK$ 131.82M ($ 16.82M)
Volume:
206.00K
Avg Vol (2M):
1.14M
Also Trade In:
Volume:
206.00K
At Loss
Avg Vol (2M):
1.14M

Business Description

Description
Hua Medicine is an investment holding company. It is engaged in development and commercialization of a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC. Some of its products are Dorzagliatin + Metformin, Dorzagliatin, Dorzagliatin + Pioglitazone and mGLUR5 NAM, among others.
Name Current Vs Industry Vs History
Cash-To-Debt 8.71
Equity-to-Asset 0.06
Debt-to-Equity 1.66
Debt-to-EBITDA -0.9
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.07
Distress
Grey
Safe
Beneish M-Score -3.59
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 21
3-Year EPS without NRI Growth Rate 20.9
3-Year Book Growth Rate -50.1
Name Current Vs Industry Vs History
5-Day RSI 66.44
9-Day RSI 58.66
14-Day RSI 54.43
6-1 Month Momentum % 4.64
12-1 Month Momentum % -52.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.24
Quick Ratio 6.06
Cash Ratio 5.8
Days Inventory 196.82
Days Sales Outstanding 44.61
Days Payable 371.72

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.8
Shareholder Yield % -8.33